改良释放型磷脂酰胆碱(LT-02)治疗溃疡性结肠炎:两项双盲、随机、安慰剂对照试验
本研究评估LT-02(新型改良释放型磷脂酰胆碱)对美沙拉秦应答不足的轻中度溃疡性结肠炎患者的诱导和维持缓解疗效。12周诱导试验(PCG-2)因无效提前终止,466例患者随机,第12周深度缓解率安慰剂13.5%、LT-02每日两次14.2%、每日四次9.7%,无统计学显著差异。48周维持试验(PCG-4)150例患者随机,第48周缓解率LT-02每日两次49.3%、美沙拉秦50.0%、安慰剂43.2%,无统计学显著差异。LT-02安全。
要点
- PCG-2诱导试验因预设中期分析显示无效而提前终止,466例随机(计划762例)。
- 第12周深度缓解率:安慰剂13.5%、LT-02每日两次14.2%、LT-02每日四次9.7%,无统计学显著差异。
- PCG-4维持试验第48周缓解率:LT-02每日两次49.3%、美沙拉秦50.0%、安慰剂43.2%,无统计学显著差异。
核心结论
- 尽管先前2期试验有磷脂酰胆碱有益的证据,本LT-02诱导试验在轻中度溃疡性结肠炎患者中因无效提前终止。
- 维持治疗中的疗效信号需在样本量足够的维持试验中确认。
- LT-02安全且耐受良好。
研究设计与样本
- 多中心双盲、随机、安慰剂对照研究,包括12周诱导试验(PCG-2)和随后48周维持试验(PCG-4)。
- PCG-2中患者按1:1:1随机接受LT-02 0.8 g每日四次、LT-02 1.6 g每日两次或安慰剂,所有患者继续口服标准剂量美沙拉秦(≥2.4 g/日)。
- PCG-4中第12周达到缓解的患者按2:1:1随机接受LT-02 1.6 g每日两次、安慰剂或美沙拉秦500 mg每日三次。
主要发现
- PCG-2因无效提前终止,466例患者随机(计划762例);第12周深度缓解率:安慰剂13.5%、LT-02每日两次14.2%、LT-02每日四次9.7%,无统计学显著差异。
- PCG-4中150例患者随机(计划约400例);第48周缓解率:LT-02每日两次49.3%、美沙拉秦50.0%、安慰剂43.2%,无统计学显著差异。
- LT-02安全。
局限性
- PCG-2因无效提前终止,仅466例随机(计划762例)。
- PCG-4仅150例随机(计划约400例)。
- 维持治疗中的疗效信号需在样本量足够的维持试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of remission in patients with mild to moderate ulcerative colitis (UC) and inadequate response to mesalamine. METHODS: LT-02 was evaluated in a multicenter double-blind, randomized, placebo-controlled study comprising a 12-week induction trial (PCG-2), followed by a 48-week maintenance trial (PCG-4). In PCG-2, patients were randomized 1:1:1 to treatment with 0.8 g LT-02 4 times daily (QID), 1.6 g LT-02 twice daily (BID), or placebo, respectively. All patients continued to take a standard dose of oral mesalamine (≥2.4 g/day). The primary end point in PCG-2 was deep remission. Patients achieving remission at week 12 were randomly assigned 2:1:1 to 1.6 g LT-02 BID, placebo, or 500 mg mesalamine (3 times daily), respectively, in PCG-4; the primary end point was remission at 48 weeks. RESULTS: PCG-2 was terminated early for futility after a prespecified interim analysis; 466 patients (of 762 planned) were randomized. There was no statistically significant difference in deep remission at week 12 (placebo, 13.5%; LT-02 BID, 14.2%; LT-02 QID, 9.7%). In PCG-4, 150 patients (of approximately 400 planned) were randomized. There was no statistically significant difference in remission rates at week 48 (LT-02 BID, 49.3%; mesalamine, 50.0%; placebo, 43.2%). LT-02 was safe. CONCLUSIONS: Despite prior evidence of beneficial effects of PC in phase 2 trials, our induction study with LT-02 in patients with mild to moderate UC was terminated prematurely for futility. Signals of efficacy in maintenance therapy require confirmation in an adequately powered maintenance trial. LT-02 was safe and well-tolerated. CLINICALTRIALS: gov: NCT02280629, NCT02142725.
引用
- Dignass A, Stremmel W, Horyński M, et al. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials. Clin Gastroenterol Hepatol. 2023. PMID: 37806372. doi:10.1016/j.cgh.2023.09.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。